Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed pancreatic cancer.~* Measurable disease.~* Absence of ascites or obstructive jaundice.~* ECOG Performance Status 0-2.~* Adequate liver kidney and bone marrow function.~* Written informed consent.~Exclusion Criteria:~* Chronic diarrheic syndrome.~* Uncontrolled brain metastases after radiation.~* Liver infiltration over 50%.~* Peripheral neuropathy ≥ 2.~* No second primary malignancy within the past 5 years, except non-melanomas skin cancer or in situ carcinoma of the cervix.~* No active uncontrolled infection.~* Active cardiac disease : unstable angina or onset of angina within last 3 months, myocardial infarction within 6 months, congestive heart failure \> class II, cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.~* Women who are pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): GEM/TAR
- 2 (Type: EXPERIMENTAL): GEM/OX/TAR

Based on this trial design, predict the completion outcome and termination type (if applicable).